Kiniksa names Ross Moat president and COO

The compensation adjustments take effect January 1, 2027, with annual base salary set at $700,000 and target bonus at 60%.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc appointed Ross Moat President and Chief Operating Officer on October 17, 2026, effective immediately. He will continue to report to Sanj K. Patel, the company’s Chairman and Chief Executive Officer. Moat has served in varying capacities at Kiniksa since June 2019 and most recently served as EVP, Chief Operating Officer, overseeing commercial, clinical, regulatory and manufacturing operations.

Effective January 1, 2027, Moat’s annual base salary will increase to $700,000 from $650,000, and his annual target bonus will increase to 60% from 55%.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Annual base salary: $700,000 Previous annual base salary: $650,000 Annual target bonus: 60% +1 more

4 metrics

Annual base salary $700,000 Effective January 1, 2027; increased from $650,000

Previous annual base salary $650,000 Before the increase effective January 1, 2027

Annual target bonus 60% Effective January 1, 2027; increased from 55%

Previous annual target bonus 55% Before the increase effective January 1, 2027

Key Terms

annual base salary, annual target bonus, related party transactions

3 terms

annual base salary financial

"annual base salary"

annual target bonus financial

"annual target bonus"

related party transactions regulatory

"related party transactions involving Mr. Moat and the Company"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Kiniksa's new president and chief operating officer?

Kiniksa appointed Ross Moat President and Chief Operating Officer, effective immediately on October 17, 2026. He will continue to report to Sanj K. Patel, the company’s Chairman and Chief Executive Officer.

What are Ross Moat's new salary and target bonus at KNSA?

Effective January 1, 2027, Moat’s annual base salary will be $700,000, up from $650,000, and his annual target bonus will be 60%, up from 55%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 04:29 PM EDT Accepted by SEC EDGAR 10/22/2026 - 04:28 PM EDT Learn about SEC filing dates

0001730430false00017304302026-10-172026-10-17

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): October 17, 2026

​

Kiniksa Pharmaceuticals International, plc

(Exact name of Registrant as Specified in Its Charter)

​

​	​	​	​	​
England and Wales	​ ​ ​	001-730430	​ ​ ​	98-1795578
(State or other jurisdiction of incorporation or organization)	​	(Commission File Number)	​	(I.R.S. Employer Identification No.)

​

105 Piccadilly, Second Floor

London, W1J 7NJ

England, United Kingdom
(781) 431-9100

(Address, zip code and telephone number, including area code of principal executive offices)

​

Kiniksa Pharmaceuticals Corp.

100 Hayden Avenue

Lexington, MA, 02421

(781) 431-9100

(Address, zip code and telephone number, including area code of agent for service)

​

N/A

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

	​		​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Class A Ordinary Shares $0.000273235 nominal value	​	KNSA	​	The Nasdaq Stock Market LLC
​	​	​	​	(Nasdaq Global Select Market)

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

On October 17, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Kiniksa Pharmaceuticals International, plc (the “Company”) appointed Ross Moat as President and Chief Operating Officer, effective immediately. Mr. Moat will continue to report to Sanj K. Patel, the Company’s Chairman and Chief Executive Officer. In addition, effective January 1, 2027, the Committee approved increases in Mr. Moat’s annual base salary and annual target bonus to $700,000 and 60% from $650,000 and 55%, respectively.

Mr. Moat has served in varying capacities at the Company since June 2019, most recently as the Company’s EVP, Chief Operating Officer. In his current position, Mr. Moat oversees the Company’s commercial, clinical, regulatory and manufacturing operations. Mr. Moat’s full biographical information is disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2026.

There are no family relationships between Mr. Moat and any director or executive officer of the Company. There are no related party transactions involving Mr. Moat and the Company requiring disclosure under Item 404(a) of Regulation S-K.

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
​	​
Date: October 22, 2026	By:	/s/ Douglas Barry
​	​	Douglas Barry
​	​	Senior Vice President, Chief Legal Officer

​

​

​

​

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 EX-101.SCH 2.6 KB
• EX-101 EX-101.LAB 14.9 KB
• EX-101 EX-101.PRE 9.4 KB